806
Participants
Start Date
February 10, 2024
Primary Completion Date
May 10, 2024
Study Completion Date
May 10, 2024
esomeprazole + amoxicillin
esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent
20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
Vonoprazan + amoxicillin
20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
Vonoprazan + amoxicillin + clarithromycin
20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
outpatient department of gastroenterology of the Third Xiangya Hospital of Central South University, Changsha
The Second People's Hospital of Huaihua
UNKNOWN
Yueyang Hospital of Traditional Chinese Medicine
UNKNOWN
The Third Xiangya Hospital of Central South University
OTHER